Results 31 to 40 of about 1,776,183 (353)

Nilotinib-Associated Destructive Thyroiditis

open access: yesCase Reports in Endocrinology, 2015
Protein tyrosine kinase inhibitors are currently an important drug class in the treatment of leukemia. They represent targeted cancer therapy and have become the treatment of choice in chronic myeloid leukemia.
Suhalia Bakerywala   +4 more
doaj   +1 more source

Advances in studies of tyrosine kinase inhibitors and their acquired resistance

open access: yesMolecular Cancer, 2018
Protein tyrosine kinase (PTK) is one of the major signaling enzymes in the process of cell signal transduction, which catalyzes the transfer of ATP-γ-phosphate to the tyrosine residues of the substrate protein, making it phosphorylation, regulating cell ...
Qinlian Jiao   +5 more
semanticscholar   +1 more source

Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

open access: yesTechnology in Cancer Research & Treatment, 2020
Background: The efficacy of next-generation epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer who have failed first-generation epidermal growth factor receptor-tyrosine kinase inhibitors ...
Yi-Tian Qi MM   +2 more
doaj   +1 more source

Challenges of drug resistance in the management of pancreatic cancer [PDF]

open access: yes, 2010
The current treatment of choice for metastatic pancreatic cancer involves single agent gemcitabine or combination of gemcitabine with capecitabine and erlotinib (tyrosine kinase inhibitor).
Akada   +119 more
core   +1 more source

Receptor Tyrosine Kinase-Targeted Cancer Therapy

open access: yesInternational Journal of Molecular Sciences, 2018
In the past two decades, several molecular targeted inhibitors have been developed and evaluated clinically to improve the survival of patients with cancer. Molecular targeted inhibitors inhibit the activities of pathogenic tyrosine kinases. Particularly,
T. Yamaoka   +4 more
semanticscholar   +1 more source

Activation of tyrosine kinases by mutation of the gatekeeper threonine. [PDF]

open access: yes, 2008
Protein kinases targeted by small-molecule inhibitors develop resistance through mutation of the gatekeeper threonine residue of the active site. Here we show that the gatekeeper mutation in the cellular forms of c-ABL, c-SRC, platelet-derived growth ...
Azam, Mohammad   +4 more
core   +1 more source

Tyrosine phosphorylation of cortactin by the FAK-Src complex at focal adhesions regulates cell motility. [PDF]

open access: yes, 2011
BackgroundCell migration plays an important role in many physiological and pathological processes, including immune cell chemotaxis and cancer metastasis.
Liao, Kan, Liu, Yang, Wang, Wenqi
core   +2 more sources

Evidence of the presence of calcium/calmodulin-dependent protein kinase IV in human sperm and its involvement in motility regulation [PDF]

open access: yes, 2005
The mechanisms involved in the regulation of mammalian sperm motility are not well understood. Calcium ions (Ca(2+)) have been suggested to play a key role in the maintenance of motility; nevertheless, how Ca(2+) modulates this process has not yet been ...
Buffone, Mariano Gabriel   +6 more
core   +1 more source

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia [PDF]

open access: yes, 2014
Bruton's tyrosine kinase (BTK) is a cytoplasmic protein found in all hematopoietic cell lineages except for T cells. BTK mediates signalling downstream of a number of receptors.
Advani   +59 more
core   +1 more source

Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor

open access: yesJournal of Biological Chemistry, 1996
Here, we have studied the activity of a novel protein-tyrosine kinase inhibitor that is selective for the Src family of tyrosine kinases. We have focused our study on the effects of this compound on T cell receptor-induced T cell activation, a process ...
J. Hanke   +7 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy